Reduction in the Risk of All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol Compared to Umeclidinium/Vilanterol in IMPACT Including Previously Missing or Censored Vital Status Data

Authors :: Steven Pascoe
Fernando J. Martinez
David A. Lipson
Dmg Halpin
G.J. Criner
Mark T. Dransfield
C.E. Jones
Robert A. Wise
Dave Singh
Sally Kilbride
MeiLan K. Han
Andrea Morris
David A. Lomas
Dawn Midwinter
Peter Lange
Nicola C. Day
P. Manchester
Source :: A102. COPD: THERAPY.
Publication Year :: 2019
Publisher :: American Thoracic Society, 2019.

Subjects :: medicine.medical_specialty
UMECLIDINIUM/VILANTEROL
business.industry
Internal medicine
Vital Status
medicine
business
Fluticasone propionate
All cause mortality
medicine.drug

Tools